ATLANTA, GA – – (Globe Newswire – August 24, 2026) – – A shareholder class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl”) (NASDAQ: GUTS). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) Revita was less effective than Defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort’s clinical sites compromised the integrity of its efficacy results; and (ii) accordingly, Revita’s clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort’s ability to assess Revita’s efficacy.

 If you purchased Fractyl shares between January 13, 2025 and January 29, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/ fractyl-health/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is October 20, 2026.